Cycuria Therapeutics has received public grant funding to expand its operations and development efforts. The exact amount remains undisclosed.
Cycuria Therapeutics has received public grant funding to expand its operations and development efforts. The exact amount remains undisclosed.
04/28/25, 11:16 AM
Location
grazIndustry
therapeutics
biotechnology
health care
Investors
Wieland Capital (Wpmb Gmb H), Aws (Austria Wirtschaftsservice Gesellschaft Mb H), Ffg (Forschungs Förderungs Gesellschaft)
Cycuria Therapeutics, a Graz, Austria-based preclinical biotechnology company, received grant funding from FFG and AWS. This funding will be used to further its operations and development efforts for novel biologics targeting tumour cells. Cycuria's lead asset, CUR-101, aims to treat acute myeloid leukaemia. The grant follows a previous Seed investment from Wieland Capital.
Company Info
Location
graz, styria, austria
Additional Info
Cycuria Therapeutics is a preclinical stage biotechnology company based in Graz, Austria. The company is developing novel biologics that selectively target both tumour cells and tumour stem cells while preserving the creation of healthy new blood cells. Its lead asset, CUR-101, is a novel protein-based targeted therapy for acute myeloid leukaemia (AML). The therapeutic rationale behind its approach has potential applications in other blood cancers and hard-to-treat solid cancers.